# Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects

> **NCT00125346** · PHASE3 · TERMINATED · sponsor: **Novartis** · enrollment: 98 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Tobramycin Inhalation Powder

## Key facts

- **NCT ID:** NCT00125346
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-09
- **Primary completion:** 2007-02
- **Final completion:** 2007-02
- **Target enrollment:** 98 (ACTUAL)
- **Why stopped:** per Data Monitoring Committee recommendation
- **Last updated:** 2011-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00125346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00125346, "Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00125346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*